Israel’s Kamada (reported here previously) has signed a deal to supply Israel’s Health ministry with its plasma-based hyperimmune immunoglobulin (IgG) product. The product treats COVID-19 patients with pneumonia and is currently in Phase 1 & 2 trials in Israel. https://nocamels.com/2020/10/kamada-deal-supply-israel-health-ministry-covid-19-antibody/ … Continue reading →

11 of the 12 trial patients treated with the IgG Covid-19 treatment from Israel’s Kamada (reported here previously) have now recovered and been discharged from hospital. https://nocamels.com/2020/09/early-trial-results-kamada-covid-19-antibodies/

Israel’s Kamada (reported here previously) has completed manufacturing the first batch of its plasma-derived Immunoglobulin G (IgG) product for Covid-19 patients. Initial vials of the antibody have been made available for compassionate use in Israel. https://www.calcalistech.com/ctech/articles/0,7340,L-3834010,00.html

Three of the first critical Covid-19 patients treated with the new IgG plasma-derived “passive vaccine” product developed by Israel’s Kamada and Hadassah Medical Center (reported here previously), have made a rapid recovery and have now been discharged from Hadassah hospital. … Continue reading →

Jerusalem’s Hadassah Hospital is cautiously optimistic after the world’s first passive immunization of a critically ill coronavirus patient. After an injection of Kamada’s IgG antibody product (see here), a CT-scan of the lungs showed some improvement and doctors are hopeful … Continue reading →